Results 51 to 60 of about 254,619 (233)
Frontiers in Behavioral Neuroscience, 2021 The serendipitous discovery of ketamine’s antidepressant effects represents one of the major landmarks in neuropsychopharmacological research of the last 50 years.
Michael Colla +4 more
doaj +1 more source
Frontiers in Psychiatry, 2011 Identifying biosignatures to assess the probability of response to an antidepressant for patients with Major Depressive Disorder (MDD) is critically needed. Functional connectivity MRI (fcMRI) offers the promise to provide such a measure.
F. Andrew eKozel +10 more
doaj +1 more source
Risk of suicide during treatment with venlafaxine, italopram, fluoxetine, and dothiepin : retrospective cohort study [PDF]
, 2006 Objective To compare the risk of suicide in adults usingthe antidepressant venlafaxine compared with citalopram, fluoxetine, and dothiepin. Design Retrospective cohort study. Setting UK General Practice Research Database. Participants 219 088 patients,
Andrews, Elizabeth +5 more
core +2 more sources
Why antidepressants are not antidepressants
Mental Health Clinician, 2012 This statement begins Dr. Ghaemi’s review of “Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression“ published in Bipolar Disorders in 2008. The article addresses a segment of the controversial evidence to be presented as part of Annual Meeting recertification programming surrounding the use of ...
openaire +2 more sources
The pharmacological management of depression – Update 2017
South African Family Practice, 2017 Depression affects nearly 350 million people worldwide. Local data indicates that approximately 17% of all South Africans will experience at least one episode of depression in their lifetime.
Elzbieta Osuch, Andre Marais
doaj +1 more source
Experimental pharmacological research regarding the antidepressant effect of associating doxepin and selegiline in normal mice [PDF]
, 2019 The severity and complexity of depression can vary widely among individuals, thus making single drug therapy ineffective in some cases. Taking this fact into account and using a mouse model, we set on investigating the possibility of obtaining a ...
Chiriță, Cornel +8 more
core +1 more source
Health Technology Assessment, 2015 Background: Individuals with a history of recurrent depression have a high risk of repeated depressive relapse/recurrence. Maintenance antidepressant medication (m-ADM) for at least 2 years is the current recommended treatment, but many individuals are ...
Willem Kuyken +10 more
doaj +1 more source
Frontiers in Pharmacology, 2019 Psychiatric disorders, including depression and schizophrenia, affect millions of individuals worldwide. However, the precise neurobiology of psychiatric disorders remains unclear. Accumulating evidence suggests that various inflammatory processes play a
Qian Ren, Qian Ren
doaj +1 more source
Statins in Depression: An Evidence-Based Overview of Mechanisms and Clinical Studies
Frontiers in Psychiatry, 2021 Background: Depression is a leading cause of disability, burdened by high levels of non-response to conventional antidepressants. Novel therapeutic strategies targeting non-monoaminergic pathways are sorely needed.
Riccardo De Giorgi +10 more
doaj +1 more source
Antidepressants versus interpersonal psychotherapy in treating depression in HIV-positive patients.
South African Journal of Psychiatry, 2012 Aim. Despite the prevalence of HIV and AIDS in South Africa reaching pandemic proportions, very few studies have been published on co-morbid depression. This study at Chris Hani Baragwanath Hospital was conducted on a group of HIV-positive patients with ...
M Y H Moosa, F Y Jeenah
doaj +1 more source